EUVIMEDOtkrijte EUVIMED
Crossref

Myricetin alleviated immunologic contact urticaria and mast cell degranulation via the PI3K /Akt/ NF‐κB pathway

Shiting Hu iD, Yonghui Zhang, Baowen Dang, Yuejing Wang iD, Guodong Zheng, Tao Zhang, Hongli An iD

Phytotherapy Research · 2023

DOI: 10.1002/ptr.7726 ↗

At a glance

Journal article in Phytotherapy Research, 2023. Written by Shiting Hu and 6 co-authors. Institution: School of Pharmacy, Xi'an Jiaotong University, Xi'an, People's Republic of China. Major MEDLINE topics: NF-kappa B, Urticaria. Cited 20 times so far (Crossref); 29 references. Funded by: National Natural Science Foundation of China, The Fundamental Research Funds for Central University and the Foundation from the Shaanxi Administration of Traditional Chinese Medicine.

SažetakSubjectsBibliografski podaciCiteRelated studies

Abstract (original language)

Immunologic contact urticaria (ICU) is characterized by the wheal and flare reaction from direct contact with a chemical or protein agent, which involves a type I hypersensitivity mediated by allergen‐specific immunoglobulin E (sIgE). Myricetin (Myr), a bioactive flavonoid, exhibits antiinflammatory activities. Our results showed that treatment with Myr could alleviate ICU symptoms, including a decrease in the number of wheals and scratching, and inhibit ear swelling in the IgE/DNFB‐induced mice. The serum level of IgE, histamine, interleukin (IL)‐4, TNF‐α, and MCP‐1 were reduced in Myr‐treated mice. Myr also attenuated mast cells (MCs) degranulation and H‐PGDS, TSLP, IL‐33, PI3K, Akt, and NF‐κB mRNA levels in ICU model. The IgE‐mediated anaphylaxis mouse models demonstrated anti‐allergic effects of Myr. In vitro analysis showed that Myr reduced IgE‐induced calcium (Ca 2+ ) influx, suppressed degranulation, and chemokine release in LAD2 cells (human primary mast cells). Myr can significantly inhibited PLCγ1, Akt, NF‐κB, and p38 phosphorylation. In conclusion, the study demonstrated that Myr alleviate ICU symptoms and inhibit mast cell activation via PI3K/Akt/NF‐κB signal pathway.

Subjects

MeSH terms (MEDLINE)

NF-kappa BUrticariaHumansAnimalsMiceMast CellsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktCell DegranulationFlavonoids

Author keywords

immunologic contact urticariamast cellsmyricetin

Substances

NF-kappa BmyricetinPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktFlavonoids

Authors and institutions

  • School of Pharmacy, Xi'an Jiaotong University, Xi'an, People's Republic of China.
  • Center for Translational Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.
  • Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.

ORCID profiles: Shiting Hu, Yuejing Wang, Hongli An

Funding

  • National Natural Science Foundation of China
  • The Fundamental Research Funds for Central University and the Foundation from the Shaanxi Administration of Traditional Chinese Medicine

Cite

APA

Hu, S., Zhang, Y., Dang, B., Wang, Y., Zheng, G., Zhang, T., & An, H. (2023). Myricetin alleviated immunologic contact urticaria and mast cell degranulation via the PI3K /Akt/ NF‐κB pathway. Phytotherapy Research. https://doi.org/10.1002/ptr.7726

Vancouver

Hu S, Zhang Y, Dang B, Wang Y, Zheng G, Zhang T, et al. Myricetin alleviated immunologic contact urticaria and mast cell degranulation via the PI3K /Akt/ NF‐κB pathway. Phytotherapy Research. 2023. doi:10.1002/ptr.7726

BibTeX
@article{Hu2023,
  author = {Hu, Shiting and Zhang, Yonghui and Dang, Baowen and Wang, Yuejing and Zheng, Guodong and Zhang, Tao and An, Hongli},
  title = {Myricetin alleviated immunologic contact urticaria and mast cell degranulation via the PI3K /Akt/ NF‐κB pathway},
  journal = {Phytotherapy Research},
  year = {2023},
  doi = {10.1002/ptr.7726}
}
Start for free →